During Thursday’s trade, Shares of American Eagle Outfitters, Inc. (NYSE:AEO), lost -3.23% to $15.30.
American Eagle Outfitters, declared its Board of Directors has designated Jay L. Schottenstein Chief Executive Officer, effective right away. Jay will continue in his role as Executive Chairman of the Board. He has served as interim Chief Executive Officer since January of 2014.
“Jay has orchestrated a swift recovery since taking the helm, successfully guiding the company through a challenging and highly competitive retail environment,” commented Michael Jesselson, Lead Independent Director for AEO’s Board of Directors. “He has exceptional instincts for our brands, a strong planned vision and proven ability to lead the company to profitable growth. On behalf of the entire Board, we are happy to have Jay’s commitment and the leadership continuity that this appointment brings.”
American Eagle Outfitters, Inc. operates as a retailer of apparel and accessories in the United States and internationally. The company’s stores offers denims, pants, shorts, sweaters, fleece, outerwear, graphic T-shirts, footwear, and accessories for 15 to 25 year old men and women under the American Eagle Outfitters brand name; and intimates and personal care products for women the aerie brand name.
Shares of Kellogg Company (NYSE:K), inclined 0.32% to $69.11, during its current trading session.
Kellogg Company - A crew of culinary influencers are inspiring home cooks to reimagine their breakfast by making delicious creations with a versatile favorite: cereal. Kellogg’s® and its breakfast brigade are encouraging families to think outside the cereal box, forever changing how they eat cereal.
From Master Chef Judge Christina Tosi, to the dynamic chefs featured at this year’s Taste Talks festivals in Brooklyn and Chicago, to talented foodie influencers featured on an array of cutting-edge digital media and content platforms such as Tongal, Philo Media, TasteMade and Meredith Xcelerated Marketing (a part of Meredith Corporation), each member of this culinary crew has created inventive new recipes using Kellogg’s cereal to truly wake up breakfast lovers’ taste buds.
Kellogg Company, together with its auxiliaries, manufactures and markets ready-to-eat cereal and convenience foods. The company operates through U.S. Morning Foods, U.S. Snacks, U.S. Specialty, North America Other, Europe, Latin America, and Asia Pacific segments. Its principal products comprise ready-to-eat cereals and convenience foods, such as cookies, crackers, savory snacks, frozen foods, toaster pastries, cereal bars, fruit-flavored snacks, frozen waffles, and veggie foods, in addition to health and wellness business bars, and beverages.
Finally, Aeterna Zentaris Inc. (NASDAQ:AEZS), lost -4.52%, and is now trading at $8.45.
Aeterna Zentaris declared the finalization of a co-marketing agreement with Armune BioScience, Inc. (“Armune”) that will allow the Company to promote Armune’s APIFINY®, the only cancer specific, non-PSA blood test for the detection of prostate cancer.
Under the co-marketing agreement, the Company will promote APIFINY to designated medical professionals in its U.S. territories and will receive a commission for each test performed resulting from its targeted promotion. Jude Dinges, Senior Vice President and Chief Commercial Officer of Aeterna Zentaris, commented on the agreement: “APIFINY represents an important addition to clinical information pertaining to the detection of prostate cancer. It is a simple, non-PSA based measure for patients and their clinicians to aid in assessment of prostate cancer risk. Importantly, this product enhances our focus on the oncology marketplace in general and on the diagnosis, monitoring and treatment of prostate cancer in particular. It was recently stated that our Zoptrex™ product has demonstrated potential as a treatment for certain types of prostate cancer in an investigator-sponsored Phase II trial and, therefore, we have a keen interest in products that relate to the condition.”
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.